输注因子XIII治疗肾移植术后难治性输尿管漏的疗效观察。

Case Reports in Transplantation Pub Date : 2020-07-16 eCollection Date: 2020-01-01 DOI:10.1155/2020/1780760
Ryoichi Maenosono, Tomohisa Matsunaga, Hajime Hirano, Hayahito Nomi, Shunri Taniguchi, Yuya Fujiwara, Koichiro Minami, Hirofumi Uehara, Teruo Inamoto, Haruhito Azuma
{"title":"输注因子XIII治疗肾移植术后难治性输尿管漏的疗效观察。","authors":"Ryoichi Maenosono,&nbsp;Tomohisa Matsunaga,&nbsp;Hajime Hirano,&nbsp;Hayahito Nomi,&nbsp;Shunri Taniguchi,&nbsp;Yuya Fujiwara,&nbsp;Koichiro Minami,&nbsp;Hirofumi Uehara,&nbsp;Teruo Inamoto,&nbsp;Haruhito Azuma","doi":"10.1155/2020/1780760","DOIUrl":null,"url":null,"abstract":"<p><p>Despite the evolution of transplantation techniques, urological complications are common and result in loss of graft. We report the case of a 57-year-old man who developed continuous urine leakage despite pyeloureteral neoanastomosis and stenting after kidney transplantation from his dizygotic twin. Suspecting ureteral leakage, we performed pyeloureteral neoanastomosis using his native right ureter and a ureteral stent 5 days after the kidney transplant. However, urine leakage continued for several days. Because the plasma factor XIII level decreased to 48%, we administered factor XIII products (Fibrogammin P; CSL Behring, King of Prussia, PA) after the surgery. Although its utility and safety in patients with renal failure and/or transplantation are unclear, urine leakage stopped after the infusion of fibrogammin without any side effects. This is the first case report of the use of factor XIII for refractory urine leakage after kidney transplantation. Although further studies are needed, administration of factor XIII products could be one option for refractory urine leakage after transplantation.</p>","PeriodicalId":30327,"journal":{"name":"Case Reports in Transplantation","volume":"2020 ","pages":"1780760"},"PeriodicalIF":0.0000,"publicationDate":"2020-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/1780760","citationCount":"0","resultStr":"{\"title\":\"Effectiveness of Factor XIII Infusion in Treatment of Refractory Ureteral Leakage after Kidney Transplantation.\",\"authors\":\"Ryoichi Maenosono,&nbsp;Tomohisa Matsunaga,&nbsp;Hajime Hirano,&nbsp;Hayahito Nomi,&nbsp;Shunri Taniguchi,&nbsp;Yuya Fujiwara,&nbsp;Koichiro Minami,&nbsp;Hirofumi Uehara,&nbsp;Teruo Inamoto,&nbsp;Haruhito Azuma\",\"doi\":\"10.1155/2020/1780760\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Despite the evolution of transplantation techniques, urological complications are common and result in loss of graft. We report the case of a 57-year-old man who developed continuous urine leakage despite pyeloureteral neoanastomosis and stenting after kidney transplantation from his dizygotic twin. Suspecting ureteral leakage, we performed pyeloureteral neoanastomosis using his native right ureter and a ureteral stent 5 days after the kidney transplant. However, urine leakage continued for several days. Because the plasma factor XIII level decreased to 48%, we administered factor XIII products (Fibrogammin P; CSL Behring, King of Prussia, PA) after the surgery. Although its utility and safety in patients with renal failure and/or transplantation are unclear, urine leakage stopped after the infusion of fibrogammin without any side effects. This is the first case report of the use of factor XIII for refractory urine leakage after kidney transplantation. Although further studies are needed, administration of factor XIII products could be one option for refractory urine leakage after transplantation.</p>\",\"PeriodicalId\":30327,\"journal\":{\"name\":\"Case Reports in Transplantation\",\"volume\":\"2020 \",\"pages\":\"1780760\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-07-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2020/1780760\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Case Reports in Transplantation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2020/1780760\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2020/1780760","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

尽管移植技术的发展,泌尿系统并发症是常见的,并导致移植物的损失。我们报告一名57岁的男性,尽管他的异卵双胞胎肾脏移植后进行肾盂输尿管新吻合和支架置入术,但仍出现持续的尿漏。由于怀疑输尿管渗漏,我们在肾移植5天后用他的原右输尿管和输尿管支架行肾盂输尿管新吻合术。然而,尿漏持续了几天。由于血浆因子XIII水平下降到48%,我们给予因子XIII产品(纤维γ蛋白P;CSL Behring, King of Prussia, PA)术后。虽然其在肾功能衰竭和/或移植患者中的效用和安全性尚不清楚,但在输注纤维甘蛋白后尿漏停止,没有任何副作用。这是首例肾移植术后应用XIII因子治疗难治性尿漏的病例报道。虽然需要进一步的研究,但给药因子XIII产品可能是移植后难治性尿漏的一种选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Effectiveness of Factor XIII Infusion in Treatment of Refractory Ureteral Leakage after Kidney Transplantation.

Effectiveness of Factor XIII Infusion in Treatment of Refractory Ureteral Leakage after Kidney Transplantation.

Effectiveness of Factor XIII Infusion in Treatment of Refractory Ureteral Leakage after Kidney Transplantation.

Effectiveness of Factor XIII Infusion in Treatment of Refractory Ureteral Leakage after Kidney Transplantation.

Despite the evolution of transplantation techniques, urological complications are common and result in loss of graft. We report the case of a 57-year-old man who developed continuous urine leakage despite pyeloureteral neoanastomosis and stenting after kidney transplantation from his dizygotic twin. Suspecting ureteral leakage, we performed pyeloureteral neoanastomosis using his native right ureter and a ureteral stent 5 days after the kidney transplant. However, urine leakage continued for several days. Because the plasma factor XIII level decreased to 48%, we administered factor XIII products (Fibrogammin P; CSL Behring, King of Prussia, PA) after the surgery. Although its utility and safety in patients with renal failure and/or transplantation are unclear, urine leakage stopped after the infusion of fibrogammin without any side effects. This is the first case report of the use of factor XIII for refractory urine leakage after kidney transplantation. Although further studies are needed, administration of factor XIII products could be one option for refractory urine leakage after transplantation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
21
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信